Skip to Content

Dasselta

Active Substance: desloratadine
Common Name: desloratadine
ATC Code: R06AX27
Marketing Authorisation Holder: Krka, d.d., Novo mesto
Active Substance: desloratadine
Status: Authorised
Authorisation Date: 2011-11-28
Therapeutic Area: Urticaria Rhinitis, Allergic, Seasonal Rhinitis, Allergic, Perennial
Pharmacotherapeutic Group: Antihistamines for systemic use

Therapeutic Indication

Dasselta is indicated for the relief of symptoms associated with:

  • allergic rhinitis;
  • urticaria.

What is Dasselta?

Dasselta is a medicine containing the active substance desloratadine. It is available as tablets (5 mg).

Dasselta is a ‘generic medicine’. This means that Dasselta is similar to a ‘reference medicine’ already authorised in the European Union (EU) called Aerius.

What is Dasselta used for?

Dasselta is used to relieve the symptoms of allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites) or urticaria (a skin condition caused by an allergy, with symptoms including itching and hives).

The medicine can only be obtained with a prescription.

How is Dasselta used?

The recommended dose for adults and adolescents (12 years of age and over) is one tablet once a day.

How does Dasselta work?

The active substance in Dasselta, desloratadine, is an antihistamine. It works by blocking the receptors on which histamine, a substance in the body that causes allergic symptoms, normally fixes itself. When the receptors are blocked, histamine cannot have its effect, and this leads to a decrease in the symptoms of allergy.

How has Dasselta been studied?

Because Dasselta is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Aerius. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

What are the benefits and risks of Dasselta?

Because Dasselta is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine’s.

Why has Dasselta been approved?

The CHMP concluded that, in accordance with EU requirements, Dasselta has been shown to have comparable quality and to be bioequivalent to Aerius. Therefore, the CHMP’s view was that, as for Aerius, the benefit outweighs the identified risk. The Committee recommended that Dasselta be given marketing authorisation.

Other information about Dasselta

The European Commission granted a marketing authorisation valid throughout the European Union for Dasselta on 28 November 2011.

For more information about treatment with Dasselta, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide